 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Beianting (bevacizumab biosimilar) / Betta Pharma, Chinese PLA General Hospital, Beijing Mabworks Biotech, finotonlimab (SCT-I10A) / Sinocelltech, Ambezhu (bevacizumab biosimilar) / Sinocelltech
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial. (Hall A; Poster Bd #: 72) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3823;
P2/3
The combination of SCT-I10A and SCT510 showed substantial clinical advantages and an acceptable safety profile in patients with advanced HCC, thereby supporting its suitability as a first-line treatment option for HCC.
- ||||| finotonlimab (SCT-I10A) / Sinocelltech, Ambezhu (bevacizumab biosimilar) / Sinocelltech
Enrollment closed, Enrollment change, Combination therapy, Metastases: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 1, 2024
P2/3, N=405, Active, not recruiting, Sponsor: Sinocelltech Ltd.
The combination of SCT-I10A and SCT510 showed substantial clinical advantages and an acceptable safety profile in patients with advanced HCC, thereby supporting its suitability as a first-line treatment option for HCC. Recruiting --> Active, not recruiting | N=621 --> 405
- || SCT510 (bevacizumab biosimilar) / Sinocelltech
Clinical, P1 data, PK/PD data, Journal: A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin) in Healthy Chinese Males. (Pubmed Central) - May 29, 2023
P1
This study demonstrated that the pharmacokinetics, safety, and immunogenicity of SCT510 were equivalent to bevacizumab (Avastin). As a proposed biosimilar drug to bevacizumab, SCT510 was well tolerated in healthy Chinese males.
- ||| Avastin (bevacizumab) / Roche, SCT510 (bevacizumab biosimilar) / Sinocelltech
New P1 trial: PK and Safety of SCT510 (clinicaltrials.gov) - Nov 8, 2021
P1, N=84, Completed, Sponsor: First Affiliated Hospital of Zhejiang University
- |||||| finotonlimab (SCT-I10A) / Sinocelltech, Ambezhu (bevacizumab biosimilar) / Sinocelltech
Enrollment open, Combination therapy, Metastases: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 12, 2020
P2/3, N=621, Recruiting, Sponsor: Sinocelltech Ltd.
As a proposed biosimilar drug to bevacizumab, SCT510 was well tolerated in healthy Chinese males. Not yet recruiting --> Recruiting
- |||||||||| finotonlimab (SCT-I10A) / Sinocelltech, Ambezhu (bevacizumab biosimilar) / Sinocelltech
New P2/3 trial, Combination therapy, Metastases: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 22, 2020
P2/3, N=621, Not yet recruiting, Sponsor: Sinocelltech Ltd.
- |||||||||| Ambezhu (bevacizumab biosimilar) / Sinocelltech
New P3 trial, Metastases: To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2019
P3, N=560, Not yet recruiting, Sponsor: Sinocelltech Ltd.